Related Experiment Video
Updated: Jul 13, 2026
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Reduced pseudocholinesterase activity in patients with HELLP syndrome
Samuel Lurie1, Oscar Sadan, Galia Oron
1Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel. lurie@nashim.net
Reproductive Sciences (Thousand Oaks, Calif.)
|July 20, 2007
Summary
Sixty percent of patients with HELLP syndrome exhibit reduced pseudocholinesterase activity, potentially impacting anesthesia. This finding highlights the need for anesthesiologists to consider altered drug metabolism in these patients.
Area of Science:
- Obstetrics and Gynecology
- Anesthesiology
- Clinical Chemistry
Background:
- HELLP syndrome is a severe pregnancy complication.
- Reduced pseudocholinesterase activity was previously observed in a HELLP syndrome patient.
- Impaired liver function was hypothesized as the cause of reduced pseudocholinesterase activity.
Purpose of the Study:
- To determine the prevalence of low pseudocholinesterase activity in patients with HELLP syndrome.
- To compare pseudocholinesterase activity in HELLP syndrome patients with severe preeclampsia and normal pregnancy controls.
- To investigate the correlation between pseudocholinesterase activity and liver function markers.
Main Methods:
- Serum pseudocholinesterase activity measured via spectrophotometry.
- Study included 15 HELLP syndrome patients, 15 severe preeclampsia patients, and 15 healthy pregnant women.
- Statistical analysis compared activity levels and correlated them with liver enzymes.
Main Results:
- Reduced pseudocholinesterase activity was found in 60% of HELLP patients, 33.3% of severe preeclampsia patients, and 6.6% of normal pregnancies (P=.009).
- Pseudocholinesterase activity correlated significantly with alanine aminotransferase (r=0.417, P=.006) and aspartate aminotransferase (r=0.462, P=.002) levels.
- A higher prevalence of reduced pseudocholinesterase activity was observed in HELLP syndrome patients.
Conclusions:
- Reduced pseudocholinesterase activity is prevalent in HELLP syndrome.
- Anesthesiologists should be aware of potential slow metabolic degradation of choline-ester drugs in HELLP patients.
- This highlights the importance of monitoring liver function and enzyme activity in HELLP syndrome management.
Related Concept Videos
01:26Anticholinesterase Agents: Poisoning and Treatment
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
01:22Cholinesterases: Distribution and Function
Cholinesterases are a group of serine hydrolase enzymes that play a crucial role in the breakdown of choline esters. The two primary types of cholinesterases are acetylcholinesterases (AChEs) and butyrylcholinesterase (BuChEs), which differ in their distribution, function, and substrate specificity. AChEs, also known as true cholinesterases, specifically hydrolyze acetylcholine, while BuChEs, often referred to as pseudocholinesterases, can hydrolyze various choline esters, including...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...